Teicoplanin

Summary

Teicoplanin (CHEMBL4297166) is a phase-3 clinical-stage unknown (ATC J01XA02); indicated across 5 conditions including bacterial infectious disease and skin disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: J01XA02
• Indications: 5 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297166
Name	Teicoplanin
Type	Unknown
Max phase	3
ATC	J01XA02

Also known as: MDL 507, MDL-507, NSC-759183, Tagocid, Targocid, Targosid, Teichomycin a2, Teicoplanin, Teicoplanin a2, Teicoplanina, Teicoplanine, Teikoplanin

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
skin disorder	3	MONDO:0005093	EFO:0000701
osteomyelitis	2	MONDO:0005246	EFO:0003102
cystic fibrosis	1	MONDO:0009061	MONDO:0009061

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE4	7
Not specified	6
PHASE3	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05914467	PHASE4	ACTIVE_NOT_RECRUITING	TDM-optimized Teicoplanin Dosing Versus Standard of Care
NCT00368498	PHASE4	UNKNOWN	A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely
NCT00454272	PHASE4	COMPLETED	Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients
NCT00719056	PHASE4	COMPLETED	Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty
NCT02018094	PHASE4	COMPLETED	The Amputation Surgical Site Infection Trial (ASSIT)
NCT04003818	PHASE4	TERMINATED	Efficacy and Safety of Teicoplanin in CDAD
NCT04370145	PHASE4	COMPLETED	Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy
NCT00430937	PHASE3	TERMINATED	Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
NCT04341831	PHASE3	UNKNOWN	Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection
NCT00428844	PHASE2	COMPLETED	Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
NCT01815541	PHASE2	COMPLETED	Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study
NCT00925093	PHASE1	WITHDRAWN	Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection
NCT02652169	Not specified	RECRUITING	PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4
NCT06426836	Not specified	RECRUITING	Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
NCT06818565	Not specified	NOT_YET_RECRUITING	Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
NCT00024453	Not specified	UNKNOWN	Teicoplanin in Treating Septicemia in Patients Who Are Receiving Chemotherapy Through a Central Venous Catheter
NCT00462878	Not specified	COMPLETED	Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation
NCT03020901	Not specified	UNKNOWN	the Clinical Trial of Teicoplanin for Injection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).